Clinical Scorecard: Impact of Dapagliflozin on Cardiac Motion Metrics and Electrophysiological Function in Individuals with Type 2 Diabetes Mellitus and Coronary Artery Disease

At a Glance

Key Highlights

• Dapagliflozin improved left ventricular ejection fraction and myocardial strain indices.
• Enhanced cardiac electrophysiological activity was observed with dapagliflozin.
• No significant difference in adverse event rates between treatment groups.
• Dapagliflozin group showed superior clinical efficacy compared to conventional treatment.
• Study included 262 patients over a 4-week treatment period.

Guideline-Based Recommendations

Diagnosis

• Evaluate cardiac function and electrophysiological parameters in patients with T2DM and CHD.

Management

• Consider adding dapagliflozin to standard therapy for improved cardiac outcomes.

Monitoring & Follow-up

• Monitor myocardial motion parameters and cardiac electrophysiological activity.

Risks

• Assess for potential adverse cardiovascular events, though rates were not significantly different in this study.

Patient & Prescribing Data

262 patients with T2DM and CHD.

Dapagliflozin 10 mg daily was added to standard therapy including metformin.

Clinical Best Practices

• Incorporate SGLT2 inhibitors like dapagliflozin in treatment plans for patients with T2DM and CHD.
• Regularly assess cardiac function and electrophysiological parameters in this population.

Related Resources & Content

• Study on Dapagliflozin Effects